Liposarcoma of the Larynx

Abstract

Cases of LLS are extremely rare. Because the histologic changes are frequently subtle, LLS can be easily mistaken for a benign tumor. As a result, the diagnosis requires a high index of suspicion and diligence in examining biopsy specimens. Computed tomography and magnetic resonance imaging can assist in the diagnosis and surgical approach. Genetic and immunostaining analysis techniques may also prove to have valuable prognostic, diagnostic, and therapeutic implications for this disease. Wide surgical excision is the mainstay of treatment. The use of radiotherapy and chemotherapy in treating this cancer remains experimental, but might be considered on a case-to-case basis for palliation or to treat aggressive variants of the disease.

Myxoid liposarcoma of the supraglottic larynx, the first Scandinavian case

“…[8] The myxoid subtype may be more susceptible to radiotherapy. [3,4] In this case, no adjuvant chemotherapy was given, as most previous authors on the subject agree is not beneficial for survival or rate of recurrence.…”

“…[1] The well-differentiated and myxoid subtypes are the most common. [2][3][4] Liposarcomas accounts for less than 1% of all malignant tumours. The primary locations are extremities and retroperitoneum and 5% of the tumours are located in the head and neck region.…”

“…[1] Liposarcomas of the upper aerodigestive tract are extremely rare with less than 40 cases reported to date in the English literature. [2,3] These tumours show male predominance 7:1,[3] 24:3. [4] The mean age at the time of diagnosis is 55 years and about half of the cases have recurrences.…”

“…[4] The mean age at the time of diagnosis is 55 years and about half of the cases have recurrences. [3,4] As with other tumours of the upper aerodigestive tract the most common symptoms are dysphonia and dysphagia. [4,5] Some tumours have been reported asymptomatic, and therefore, may result in tumours of substantial size at the time of diagnosis.…”

“…The 5-year survival rate is relatively high, although varying between subtypes: welldifferentiated 85-100%, myxoid 77-95%, pleomorphic 21-45% and around 30% for de-differentiated. [3] The pathogenesis is believed to be associated with either translocation t(12;16)(q13;p11.2) or abnormalities of 1q and 12q13, which encodes the DDIT3 gene (formerly CHOP) which is necessary for adipocyte differentiation. [6,7] Although a rare neoplasm with a relative high 5-year survival rate, the size (resulting in postoperative morbidity), recurrence rate and de-differentiation over time makes this a relevant subject.…”